Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 440 | $270.97 | $119,225.00 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.6400 to $271.5000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 9,079 | $108.49 | $984,980.71 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 2,577 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · derivative · entry 12 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,909 Underlying: Common Stock · 2,577 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 500 | $272.26 | $136,130.00 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 10 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,307 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0900 to $272.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,663 | $271.40 | $451,341.36 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,807 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0700 to $271.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 414 | $270.56 | $112,010.47 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,470 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0700 to $271.0500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 2,577 | $108.49 | $279,578.73 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 21,502 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · derivative · entry 11 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,486 Underlying: Common Stock · 21,502 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,269 | $274.52 | $348,362.96 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,307 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.2700 to $275.0300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,934 | $273.71 | $529,358.04 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,576 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.2300 to $274.2200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 4,947 | $272.34 | $1,347,256.09 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,510 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0100 to $272.9500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 3,781 | $271.53 | $1,026,667.41 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,457 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0000 to $271.9900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 9,571 | $270.45 | $2,588,507.58 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,238 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0000 to $270.9800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 21,502 | $108.49 | $2,332,751.98 |
DisclosureSEC source: 0000914190-20-000237 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 7,909 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · derivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,909 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 709 | $264.01 | $187,184.44 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6168 to $264.5700, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 2,100 | $262.68 | $551,619.39 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.3150 to $263.2300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 3,400 | $261.74 | $889,926.54 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,809 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.2500 to $262.2400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 1,700 | $260.83 | $443,409.64 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,209 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.2500 to $261.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 7,909 | $108.49 | $858,047.41 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:13 UTC |
WIENS HAROLD JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0001562180-20-004079 · primarydocument.xml · derivative · entry 4 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,985 shares Expires 2026-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:13 UTC |
WIENS HAROLD JDirector
|
SaleCommon Stock | 3,985 | $260.00 | $1,036,100.00 |
DisclosureSEC source: 0001562180-20-004079 · primarydocument.xml · nonDerivative · entry 3 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,843 Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:13 UTC |
WIENS HAROLD JDirector
|
Exercise / conversionCommon Stock | 3,985 | $101.19 | $403,242.15 |
DisclosureSEC source: 0001562180-20-004079 · primarydocument.xml · nonDerivative · entry 2 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,995 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,995 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,600 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 3,800 | $260.38 | $989,453.50 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0800 to $261.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 2,195 | $259.72 | $570,079.25 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,111 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.0500 to $260.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 1,600 | $94.35 | $150,960.00 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 5,995 | $108.49 | $650,397.55 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,448 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · derivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,909 Underlying: Common Stock · 3,448 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 3,448 | $260.19 | $897,134.09 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0000 to $260.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 3,448 | $108.49 | $374,073.52 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:41 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 21,159 | $0.00 Strike: $86.25 | $0.00 |
DisclosureSEC source: 0000914190-20-000186 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,157 Underlying: Common Stock · 21,159 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:41 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 13,018 | $266.40 | $3,467,995.20 |
DisclosureSEC source: 0000914190-20-000186 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,130 F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:41 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 21,159 | $86.25 | $1,824,963.75 |
DisclosureSEC source: 0000914190-20-000186 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 8,637 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · derivative · entry 10 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,357 Underlying: Common Stock · 8,637 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,963 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · derivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,963 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 4,924 | $268.41 | $1,321,636.07 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.09 to $268.81, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 7,676 | $267.63 | $2,054,289.50 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,924 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.09 to $268.05, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 8,637 | $108.49 | $937,028.13 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 3,963 | $94.35 | $373,909.05 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed Jun 2, 2020 21:13 UTC |
WIENS HAROLD JDirector
|
GiftCommon Stock | 378 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004079 · primarydocument.xml · nonDerivative · entry 1 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,843 F1 · shares: Represents a transfer of shares to a charitable donor advised fund. The reporting person retained no pecuniary interest in the transferred shares. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Options (right to Buy) · Derivative | 5,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · derivative · entry 6 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 125 | $267.94 | $33,492.58 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 5 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,221 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.82 to $267.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 1,974 | $267.32 | $527,685.34 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 4 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,346 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.82 to $267.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 1,601 | $266.07 | $425,979.03 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,320 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.68 to $266.6712, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 1,300 | $265.35 | $344,959.81 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,921 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.64 to $265.6276, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 5,000 | $70.35 | $351,750.00 |
DisclosureSEC source: 0000914190-20-000182 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 11,037 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · derivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,963 Underlying: Common Stock · 11,037 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 900 | $268.89 | $241,996.50 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.58 to $269.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.